StockData
vTv Therapeutics Inc. logo

vTv Therapeutics Inc. (VTVT) stock

VTVTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3064% below fair value
$16.23−1.06 (-6.13%)

Close on Nov 18, 2026Market cap $64.17MP/E –Yield –

vTv Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

vTv Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$9.25M. For fiscal 2025 it was -$32.81M. The highest annual figure on record is -$11.85M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$32.81M–
FY2024Dec 31, 2024-$24.18M–
FY2023Dec 31, 2023-$25.50M–
FY2022Dec 31, 2022-$22.54M–
FY2021Dec 31, 2021-$21.66M–
FY2020Dec 31, 2020-$11.85M–
FY2019Dec 31, 2019-$20.89M–
FY2018Dec 31, 2018-$19.82M–
FY2017Dec 31, 2017-$50.68M–
FY2016Dec 31, 2016-$55.02M–
FY2015Dec 31, 2015-$38.14M–
FY2014Dec 31, 2014-$28.90M–
FY2013Dec 31, 2013-$35.83M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$13.93M–
Q1 FY2026Mar 31, 2026$23.26M–
Q4 FY2025Dec 31, 2025-$7.89M–
Q3 FY2025Sep 30, 2025-$10.70M–
Q2 FY2025Jun 30, 2025-$7.72M–
Q1 FY2025Mar 31, 2025-$6.50M–
Q4 FY2024Dec 31, 2024-$4.89M–
Q3 FY2024Sep 30, 2024-$6.51M–
Q2 FY2024Jun 30, 2024-$7.16M–
Q1 FY2024Mar 31, 2024-$5.63M–
Q4 FY2023Dec 31, 2023-$4.71M–
Q3 FY2023Sep 30, 2023-$5.37M–
Q2 FY2023Jun 30, 2023-$8.00M–
Q1 FY2023Mar 31, 2023-$7.43M–
Q4 FY2022Dec 31, 2022-$6.34M–
Q3 FY2022Sep 30, 2022-$5.69M–
Q2 FY2022Jun 30, 2022-$4.03M–
Q1 FY2022Mar 31, 2022-$6.48M–
Q4 FY2021Dec 31, 2021-$11.11M-707.0%
Q3 FY2021Sep 30, 2021-$1.60M–
Q2 FY2021Jun 30, 2021-$4.67M–
Q1 FY2021Mar 31, 2021-$4.28M–
Q4 FY2020Dec 31, 2020$1.83M–
Q3 FY2020Sep 30, 2020-$2.83M–
Q2 FY2020Jun 30, 2020-$4.20M–
Q1 FY2020Mar 31, 2020-$6.65M–
Q4 FY2019Dec 31, 2019-$6.39M–
Q3 FY2019Sep 30, 2019-$5.43M–
Q2 FY2019Jun 30, 2019-$4.79M–
Q1 FY2019Mar 31, 2019-$4.29M–
Q4 FY2018Dec 31, 2018-$351.00K–
Q3 FY2018Sep 30, 2018-$1.48M–
Q2 FY2018Jun 30, 2018-$8.86M–
Q1 FY2018Mar 31, 2018-$9.13M–
Q4 FY2017Dec 31, 2017-$12.77M–
Q3 FY2017Sep 30, 2017-$11.54M–
Q2 FY2017Jun 30, 2017-$12.62M–
Q1 FY2017Mar 31, 2017-$13.75M–
Q4 FY2016Dec 31, 2016-$13.31M–
Q3 FY2016Sep 30, 2016-$13.53M–

More vTv Therapeutics figures

See a number that looks wrong?